SCHEMBL24610250

SCHEMBL24610250

CC(C)NC(O)CCOc1ccc(-c2nnc(Nc3ccc4[nH]ncc4c3)[nH]2)cc1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ROCK2 O75116 12/20 0.42
▸ ROCK1 Q13464 4/20 0.41
▸ MEN1 O00255 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ NPC1 O15118 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ TNIK Q9UKE5 1/20 0.40
▸ CACNA2D1 P54289 1/20 0.38
▸ KDR P35968 1/20 0.38
▸ SMO Q99835 1/20 0.38
▸ CLK2 P49760 1/20 0.38
▸ BLK P51451 1/20 0.38
▸ CSNK2A1 P68400 1/20 0.38
▸ STK3 Q13188 1/20 0.38
▸ DYRK1A Q13627 1/20 0.38
▸ AURKB Q96GD4 1/20 0.38
▸ CLK4 Q9HAZ1 1/20 0.38
▸ STK17A Q9UEE5 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21198538 0.86 ROCK2 (0.56) ROCK2ROCK1MEN1KMT2ANPC1
SCHEMBL21217815 0.85 ROCK2 (0.53) ROCK2ROCK1MEN1KMT2ANPC1
SCHEMBL22966736 0.84 ROCK1 (0.51) ROCK2ROCK1MEN1KMT2ANPC1
SCHEMBL22966729 0.83 TNIK (0.44) ROCK2ROCK1MEN1KMT2ANPC1
SCHEMBL24610341 0.83 TNIK (0.45) ROCK2ROCK1MEN1KMT2ANPC1
SCHEMBL21217532 0.82 TNIK (0.44) ROCK2ROCK1MEN1KMT2ANPC1
SCHEMBL21217821 0.82 ROCK1 (0.60) ROCK2ROCK1MEN1KMT2ANPC1
SCHEMBL21217893 0.82 ROCK1 (0.46) ROCK2ROCK1MEN1KMT2ANPC1
SCHEMBL24094169 0.82 NPC1 (0.55) ROCK2ROCK1MEN1KMT2ANPC1
SCHEMBL22966756 0.82 MEN1 (0.44) ROCK2ROCK1MEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230021916-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE REDX PHARMA LIMITED (GB) 2023-01-26 — — US disclosed
EP-4026834-A1 HETEROCYCLYLAMINO-SUBSTITUTED TRIAZOLES AS MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE Redx Pharma Plc (GB) 2022-07-13 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230021916-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE ROCK2, ROCK1, RHOA ROCK2 1/4885ROCK1 2/4885MEN1 2942/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback